Cellino appoints Ed Tekeian as chief operating officer
Cellino has appointed Ed Tekeian as Chief Operating Officer, a strategic move to enhance its operational leadership as the company expands its infrastructure for personalized cell-based therapies. Tekeian, who joined Cellino in 2024 as Senior Vice President of Engineering, will now oversee operations in engineering, platform development, and manufacturing, focusing on the company’s autonomous biomanufacturing systems for patient-specific regenerative medicines.
This appointment is significant for the longevity and healthspan field, as Cellino aims to scale its production of high-quality induced pluripotent stem cells (iPSCs). These advancements are crucial for developing personalized regenerative therapies, potentially transforming treatment paradigms for various diseases. Tekeian’s extensive experience in engineering and operations across multiple sectors will support Cellino’s mission to make these therapies more accessible and effective.
For professionals in the field, Tekeian’s leadership may accelerate innovation in scalable cell production technologies, paving the way for breakthroughs in regenerative medicine. I encourage you to read the full article for more insights into Cellino’s ambitious plans.